Introduction
high total serum concentration of carnitine results predominantly from an increase in -carnitine esters, Recombinant human erythropoietin (rhEpo) is widely i.e. acylcarnitine. As a result of the reduction in free used for correction of anaemia in patients with endcarnitine, the ratios of free/total carnitine and free stage renal disease ( ESRD). In some countries, the carnitine/acylcarnitine are decreased in dialysis patients cost of rhEpo treatment accounts for up to 10% of [9] . It has been suggested that a decreased ratio of free total costs for chronic haemodialysis treatment. There carnitine to acylcarnitine resp. free carnitine to total is, therefore, a strong incentive to reduce the rhEpo carnitine indicates carnitine deficiency. requirement in dialysis patients by ancillary measures.
Plasma concentrations of -carnitine and its subfracStrategies with proven efficacy to reduce rhEpo requiretions may not be an adequate reflection of carnitine ment include: iron supplementation, subcutaneous deficiency or carnitine availability in tissues and cells, mode of administration (compared with i.v. adminisi.e. the site where -carnitine acts. Free carnitine contration), correction of hyperparathyroidism, treatment centrations in muscle have been reported to be subnorof infections and correction of aluminium intoxication.
mal in haemodialysis patients [10] . Savica et al.
[11] Several less well-proven procedures have recently reported a correlation between plasma free carnitine been summarized by Hö rl [1] among them the and muscle free carnitine. administration of -carnitine. Against the above backIn contrast to muscle, erythrocyte intracellular free ground it appears appropriate to discuss the evidence carnitine concentrations are increased whereas the conwhich argues for this suggestion [1] .
centrations of acylcarnitine are comparable to normal controls; this results in an increased ratio of free to total carnitine [12] .
Is -carnitine deficiency found in patients on
The underlying mechanism of such changed plasma maintenance haemodialysis?
and cellular concentrations of carnitine and its subfractions has not been clarified. Intestinal absorption seems Whether -carnitine deficiency exists in dialysis patients to be unchanged in dialysis patients [13] . There is has not been established beyond doubt. In patients limited information on the effect of -carnitine with preterminal renal failure, some authors have supplementation on the plasma concentration of -reported that serum concentrations of both free and carnitine and its subfractions. Predialysis free plasma total carnitine were increased, while the ratio of free carnitine concentrations increased after oral -carnitcarnitine to acylcarnitine was decreased in uraemic ine. Unchanged free carnitine, but increased total patients compared with controls [2] [3] [4] . The small carnitine plasma concentrations, have been found after water-soluble carnitine molecule is dialysable and a i.v. carnitine substitution [12] . As a consequence, the 75% decrease in plasma concentration has been noted ratio of free -carnitine to total -carnitine decreased during dialysis sessions [5] . Several hours after dialysis, [12] . however, -carnitine concentrations return to predialytic values as a consequence of re-equilibration, i.e. the return of -carnitine from tissue stores to the Does -carnitine affect increased erythrocyte extracellular space. According to some authors, in fragility in uraemic patients? patients who have been dialysed for many years, the post-dialytic rebound of free -carnitine serum concentration is attenuated, and even a gradual decrease of By what mechanism could -carnitine affect erythrocytes or erythroblasts? -carnitine may influence predialytic free or total -carnitine is observed [6 ] .
Reduced predialytic serum concentrations of free -erythrocyte stability and this would be consistent with a salutary effect of -carnitine on erythrocyte survival. carnitine, compared with healthy controls, have been found by some authors [3, 7, 8] . In contrast, normal or Alternative or complementary mechanisms of action of carnitine, e.g. on erythropoiesis, cannot be excluded, even elevated plasma concentrations of total carnitine however, particularly since Trovato et al. [14] reported that -carnitine increased reticulocyte counts. In dia- by~50% [4, 15] . Experimental studies and some clin-ical observations suggest that -carnitine increases 23.1±5.32% to 26.5±4.36% after administration of 1 g/day carnitine per os for 6 months in 12 haemodiaerythrocyte survival. -carnitine affects several erythrocyte characteristics which determine erythrocyte via-lysis patients. Similar results were found in a second study of 11 haemodialysis patients who were dialysed bility, e.g. osmotic resistance, stability under shear stress, Na+−K+-ATPase, etc. In the study by Bayon with a dialysate containing 100 mmol/l -carnitine.
These results were subsequently confirmed in doubleet al. [16 ] in vivo administration of carnitine increased the osmotic resistance of rat erythrocytes. This obser-blind, placebo-controlled studies by Bellinghieri et al.
[10]. A persistent long-lasting effect of carnitine adminvation is of interest since Matsumura et al. [9] found a reduced osmotic stability of erythrocytes, determined istration was also noted in a placebo-controlled study by Trovato et al. [14] ; a continuous increase in haemby using a coil planet centrifuge method, and low plasma -carnitine concentrations in 26 chronic haemo-atocrit was noted from 25.5±1.43% to 37.4±2.2% during 12 months of administration of -carnitine. dialysis patients. In this study a direct correlation was noted between the haemolysis endpoint and the plasma During the same interval haematocrit decreased in the placebo-controlled group from 24.0±3.58% to concentration of total carnitine and acylcarnitine. Furthermore, a significant correlation was found 21.8±3.15%. The increase in haematocrit was paralleled by a progressive increase in absolute reticulocyte between the haemolysis maximum point and the plasma concentration of total and free carnitine.
count by 40-60% in the carnitine, but not in the placebo group. Artefactual changes of iron status are Arduini et al. [17] noted that impaired mechanical stability of erythrocytes was improved by -carnitine, excluded by the observation that the serum ferritin and transferrin levels remained constant and comparwhile erythrocyte deformability remained unaffected. It has been postulated that -carnitine stabilizes the able in both groups throughout the entire study period.
All patients received 10 mg sodium ferrigluconate erythrocyte membrane by improving the uptake of the lipids which form the plasma membrane. Radiolabelled intravenously at the end of the dialysis sessions. These observations in non-rhEpo-treated patients suggested carbon of acetylcarnitine was shown to accumulate in the phospholipid and triglyceride fractions, the major that carnitine therapy might also permit more efficient use of rhEpo. A beneficial effect of -carnitine on components of the erythrocyte membrane [18, 19] . It is not only the composition and mechanical properties haemoglobin during rhEpo therapy in haemodialysis patients has been noted by several authors, e.g. of erythrocytes that may be influenced. Carnitine may also affect functional properties of the erythrocyte Kooistra et al.
[24], Boran et al. [25] , Patrikarea et al.
[26 ] and Kavadias et al. [27] . In a prospective placebomembrane e.g. the activity of the Na+−K+-pump of the erythrocyte membrane. The activity of the controlled study Labonia et al. [22] administered 1 g -carnitine i.v. after each dialysis session and this Na+−K+-pump is instrumental in the maintenance of the biconcave discoid shape of erythrocytes. The activ-reduced rhEpo requirement from 102±52.6 to 63.3±37.8 U/kg/week, while the rhEpo requirement ity of Na+−K+-ATPase of erythrocytes is inhibited by the addition of uraemic plasma [20, 21] , which reduces remained constant in the placebo group. In 14 haemodialysis patients under maintenance rhEpo therapy the number of pump sites, particularly in young erythrocytes. Labonia et al. [22] noted an increase of 0.04-0.06 g/kg/week -carnitine i.v. (corresponding to 1 g -carnitine at the end of each dialysis) resulted in Na+−K+-pump activity of the erythrocyte membrane in uraemic patients after supplementation of -carnit-a decrease in rhEpo requirement from 151±30.6 to 87.5±31.6 U/kg/week. Haemoglobin levels were ine. Carnitine increased ouabain-sensitive sodium efflux without changing the ouabain-insensitive sodium-pot-unchanged or even increased in -carnitine-treated patients despite a significantly reduced rhEpo dose. In assium cotransport or sodium-lithium cotransport. The authors concluded that carnitine deficiency may a recent placebo-controlled study, Kletzmayr et al. [4] reported a reduced rhEpo requirement (−36.9±23%) play a role in the well-known dysfunction of Na+−K+-pump activity in uraemic patients. An elegant mechan-in 42% of 20 haemodialysis patients treated with carnitine (5 or 25 mg/kg/dialysis i.v. after each dialysis istic explanation has been provided by Donatelli et al. [19] . Circulating free fatty acids are endogenous inhib-session). Fifty-eight per cent of patients did not respond to the -carnitine therapy and maintenance of itors of the Na+−K+-ATPase. -Carnitine increases delivery of free fatty acid to the mitochondria for a stable haemoglobin necessitated a constant rhEpo dose. The authors did not find significant differences oxidation and as a result the plasma concentration of free fatty acids decreases and the inhibition of the in free or total carnitine plasma concentrations between responders and non-responders. Carnitine concentraNa+−K+-ATPase is reversed. The longer lifespan of rat blood cells after treatment with -carnitine would tions tended to be higher in patients in whom anaemia improved under carnitine therapy. No significant corbe in agreement with this idea.
relation between plasma concentrations of free or total carnitine and rhEpo requirement or haemoglobin could Does administration of -carnitine improve be found. In 42 ESRD patients without carnitine anaemia?
treatment, Kooistra et al.
[24] noted a significant correlation between rhEpo dose and total plasma carnitine concentration (Pearson correlation coefficient, Many years ago in an uncontrolled study, Albertazzi et al. [23] reported that the haematocrit increased from 0.58; P<0.05).
Muraboto H. Correlation between serum carnitine levels and
The mechanisms by which carnitine may have erythrocyte osmotic fragility in hemodialysis patients. Nephron reduced the rhEpo requirement are still unknown. 
